CN1750822A - 治疗术后恶心和呕吐的方法 - Google Patents

治疗术后恶心和呕吐的方法 Download PDF

Info

Publication number
CN1750822A
CN1750822A CNA2004800045134A CN200480004513A CN1750822A CN 1750822 A CN1750822 A CN 1750822A CN A2004800045134 A CNA2004800045134 A CN A2004800045134A CN 200480004513 A CN200480004513 A CN 200480004513A CN 1750822 A CN1750822 A CN 1750822A
Authority
CN
China
Prior art keywords
palonosetron
purposes
pharmaceutically acceptable
acceptable salt
ponv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800045134A
Other languages
English (en)
Chinese (zh)
Inventor
路易吉·巴罗尼
阿尔贝托·马乔基
恩里科·布拉格里亚
里卡尔多·布拉格里亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helsinn Healthcare SA
Original Assignee
Helsinn Healthcare SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32908576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1750822(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare SA filed Critical Helsinn Healthcare SA
Publication of CN1750822A publication Critical patent/CN1750822A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
CNA2004800045134A 2003-02-18 2004-02-18 治疗术后恶心和呕吐的方法 Pending CN1750822A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44834203P 2003-02-18 2003-02-18
US60/448,342 2003-02-18

Publications (1)

Publication Number Publication Date
CN1750822A true CN1750822A (zh) 2006-03-22

Family

ID=32908576

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800045134A Pending CN1750822A (zh) 2003-02-18 2004-02-18 治疗术后恶心和呕吐的方法

Country Status (31)

Country Link
US (1) US20060074101A1 (enExample)
EP (2) EP2258367A3 (enExample)
JP (1) JP2006517944A (enExample)
KR (1) KR101113087B1 (enExample)
CN (1) CN1750822A (enExample)
AT (1) ATE490774T1 (enExample)
AU (1) AU2004212704B2 (enExample)
BR (1) BRPI0407549A (enExample)
CA (1) CA2515946C (enExample)
CU (1) CU23587B7 (enExample)
CY (1) CY1111312T1 (enExample)
DE (1) DE602004030424D1 (enExample)
DK (1) DK1596862T3 (enExample)
EA (1) EA013836B1 (enExample)
EC (1) ECSP055970A (enExample)
ES (1) ES2357769T3 (enExample)
GE (1) GEP20104908B (enExample)
HR (1) HRP20050709A2 (enExample)
IS (1) IS7983A (enExample)
MX (1) MXPA05008757A (enExample)
MY (1) MY143789A (enExample)
NO (1) NO20054296L (enExample)
NZ (1) NZ541862A (enExample)
PL (1) PL378122A1 (enExample)
PT (1) PT1596862E (enExample)
SI (1) SI1596862T1 (enExample)
TW (1) TWI355936B (enExample)
UA (1) UA96254C2 (enExample)
UY (1) UY28193A1 (enExample)
WO (1) WO2004073714A1 (enExample)
ZA (1) ZA200506580B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678064B (zh) * 2007-04-10 2016-03-16 赫尔辛医疗股份公司 使用生长激素促泌素治疗或预防呕吐之方法
CN106421793A (zh) * 2009-11-18 2017-02-22 赫尔辛医疗股份公司 用于治疗中枢介导的恶心及呕吐的组合物及方法
CN108703960A (zh) * 2018-07-25 2018-10-26 无锡鑫连鑫生物医药科技有限公司 一种帕洛诺司琼缓释微球及其制备方法和使用方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003302072A1 (en) * 2002-11-15 2004-06-15 Helsinn Healthcare Sa Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
AU2007211091B8 (en) * 2006-01-27 2013-08-29 Adare Pharmaceuticals, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
KR20140088230A (ko) * 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
NZ576237A (en) * 2006-10-24 2011-12-22 Helsinn Healthcare Sa Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability
US20090155363A1 (en) * 2007-12-14 2009-06-18 Todd Maibach Methods for oral administration of active drugs
EP2286814B1 (en) 2008-05-15 2013-10-16 Hisamitsu Pharmaceutical Co., Inc. Transdermal preparation containing palonosetron
US20100143461A1 (en) * 2008-12-08 2010-06-10 Ben-Zion Solomon Palonosetron formulation
ES2432618T3 (es) * 2009-05-20 2013-12-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
PL2432467T3 (pl) 2009-05-20 2018-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Zastosowanie antagonistów receptora 5-ht3 serotoniny w leczeniu zaburzeń przedsionkowych ze zmianami chorobowymi
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US20120253046A1 (en) 2009-11-13 2012-10-04 Helsinn Healthcare S.A. Palonosetron metabolites
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
KR101368587B1 (ko) 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
US10071088B2 (en) 2012-06-26 2018-09-11 Precondit, Llc Anti-nausea drug combinations
WO2015099381A1 (ko) 2013-12-23 2015-07-02 주식회사 삼양바이오팜 팔로노세트론을 함유하는 약학 조성물
SI3442537T1 (sl) 2016-04-14 2024-05-31 Sensorion (+)-azasetron za uporabo pri zdravljenju ušesnih obolenj
JP6768404B2 (ja) * 2016-08-12 2020-10-14 武田テバファーマ株式会社 パロノセトロン又はその薬学的に許容される塩を含む医薬組成物
JP6705348B2 (ja) * 2016-09-23 2020-06-03 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
KR101802183B1 (ko) * 2016-11-16 2017-11-28 주식회사 유영제약 팔로노세트론을 활성성분으로 함유하는 약제학적 조성물
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
ES2943933T3 (es) 2018-01-12 2023-06-16 Orion Corp Colirios de palonosetrón para el tratamiento o la prevención de náuseas y vómitos

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US4937247A (en) 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
EP0200444B1 (en) 1985-04-27 1992-11-11 Beecham Group Plc Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity
US5240954A (en) 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
GB8516083D0 (en) 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5578628A (en) 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US4906755A (en) 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US4707484A (en) 1986-11-25 1987-11-17 Hoffmann-La Roche Inc. Substituted piperidinomethylindolone and cyclopent(b)indolone derivatives
US5011846A (en) 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
KR970007917B1 (ko) * 1989-11-28 1997-05-17 신텍스 인크. 신규 삼환식 화합물
US5189041A (en) 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists
US5137893A (en) 1991-03-07 1992-08-11 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5491148A (en) 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
GB9305593D0 (en) 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US5492914A (en) 1994-07-28 1996-02-20 Syntex (U.S.A.) Inc. 2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]is[2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423588D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US6294548B1 (en) 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
WO1999064046A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-ht3 receptors
CA2340225A1 (en) * 1998-10-27 2000-05-04 Wesley Wehsin Han Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap
US6196963B1 (en) * 1999-03-02 2001-03-06 Medtronic Ave, Inc. Brachytherapy device assembly and method of use
WO2003100091A1 (en) * 2002-05-24 2003-12-04 Epidauros Biotechnologie Ag Means and methods for improved treatment using 'setrones'
AU2003302072A1 (en) * 2002-11-15 2004-06-15 Helsinn Healthcare Sa Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) * 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678064B (zh) * 2007-04-10 2016-03-16 赫尔辛医疗股份公司 使用生长激素促泌素治疗或预防呕吐之方法
CN106421793A (zh) * 2009-11-18 2017-02-22 赫尔辛医疗股份公司 用于治疗中枢介导的恶心及呕吐的组合物及方法
CN106421793B (zh) * 2009-11-18 2023-06-16 赫尔森保健股份公司 用于治疗中枢介导的恶心及呕吐的组合物及方法
CN108703960A (zh) * 2018-07-25 2018-10-26 无锡鑫连鑫生物医药科技有限公司 一种帕洛诺司琼缓释微球及其制备方法和使用方法

Also Published As

Publication number Publication date
CA2515946A1 (en) 2004-09-02
BRPI0407549A (pt) 2006-02-14
US20060074101A1 (en) 2006-04-06
ATE490774T1 (de) 2010-12-15
NO20054296D0 (no) 2005-09-16
CU23587B7 (es) 2010-10-30
AU2004212704A1 (en) 2004-09-02
NO20054296L (no) 2005-11-17
IS7983A (is) 2005-08-15
EA200501318A1 (ru) 2006-02-24
EP2258367A2 (en) 2010-12-08
KR20050121671A (ko) 2005-12-27
MXPA05008757A (es) 2006-05-31
CY1111312T1 (el) 2015-08-05
PT1596862E (pt) 2011-03-15
ECSP055970A (es) 2006-01-16
PL378122A1 (pl) 2006-03-06
ES2357769T3 (es) 2011-04-29
HRP20050709A2 (en) 2005-12-31
EA013836B1 (ru) 2010-08-30
JP2006517944A (ja) 2006-08-03
GEP20104908B (en) 2010-03-10
CA2515946C (en) 2008-12-02
HK1076402A1 (en) 2006-01-20
UA96254C2 (uk) 2011-10-25
DK1596862T3 (da) 2011-03-28
WO2004073714A1 (en) 2004-09-02
ZA200506580B (en) 2006-06-28
EP1596862B1 (en) 2010-12-08
DE602004030424D1 (de) 2011-01-20
EP1596862A1 (en) 2005-11-23
NZ541862A (en) 2008-04-30
TWI355936B (en) 2012-01-11
MY143789A (en) 2011-07-15
EP2258367A3 (en) 2011-07-13
UY28193A1 (es) 2004-09-30
TW200418474A (en) 2004-10-01
SI1596862T1 (sl) 2011-03-31
AU2004212704B2 (en) 2009-10-01
KR101113087B1 (ko) 2012-02-15

Similar Documents

Publication Publication Date Title
CN1750822A (zh) 治疗术后恶心和呕吐的方法
US6248789B1 (en) Administration of ketamine to manage pain and to reduce drug dependency
TWI764951B (zh) 用於處理疼痛之右美托咪啶經皮遞送裝置
CN109562281B (zh) 酚类trpv1激动剂的前药与局部麻醉药和血管收缩剂联合用于改善局部麻醉
TW200418475A (en) Treatment of pain with combinations of nalbuphine and other kappa-opioid receptor agonists and opioid receptor antagonists
CA2230690C (en) Administration of ketamine to manage pain and to reduce drug dependency
MX2013003832A (es) Formulaciones y metodos para atenuar la depresion respiratoria inducida por sobredosis de opioides.
JP2002519310A (ja) 疼痛軽減のための方法および経皮組成物
TWI473614B (zh) Anti-analgesic inhibitors
US20240342156A1 (en) Methods for treating pain
US20060110333A1 (en) Composition for nasal absorption
AU2020397173A1 (en) Use of a KV7 potassium channel opener for treating pain
US10874658B2 (en) Sublingual opioid formulations containing naloxone
Bronkhorst et al. Pholcodine: treatment options for dry cough
US20220233492A1 (en) Method of preventing or treating postoperative pain
US10736874B1 (en) Methods for treating pain associated with sickle cell disease
US8791093B2 (en) Pharmaceutical delivery systems for treatment of substance abuse and other addictions
HK1076402B (en) Use of palonosetron for treating post-operative nausea and vomiting
CN1402638A (zh) 一种治疗物质成瘾的方法
Patel et al. Opioid Side Effects
CN1780628A (zh) 包含组织蛋白酶s抑制剂和阿片类物质的药物组合物
AU2017213491A1 (en) Formulations and methods for attenuating respiratory depression induced by opioid overdose

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20060322